Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition or CD2 plus CD28 pathways

Transplantation

Volumn 62, Issue 7, 1996, Pages 1011-1018

  Woodward, Jennifer E ^a   Qin, Lihui ^b   Chavin, Kenneth D ^a   Lin, Jixun ^a   Tono, Takeshi ^b   Ding, Yaozhong ^a,b   Linsley, Peter S ^c   Bromberg, Jonathan S ^a,d   Baliga, Prabhakar ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD28 ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE RECEPTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT SURVIVAL; HEART GRAFT; IMMUNOLOGICAL TOLERANCE; MIXED LYMPHOCYTE REACTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; PREGNANCY; RATS; SECOND MESSENGER SYSTEMS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0029851220     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00021     Document Type: Article

References (47)

1. Marrack P, Kappler J. The T cell receptor. Science 1987; 238: 1073.
2. Weiss A. Structure and function of the T cell antigen receptor. J Clin Invest 1990; 86: 1015.
3. Bierer BE, Burakoff SJ. T-lymphocyte activation: the biology and function of CD2 and CD4. Immunol Rev 1989; 111: 267.
4. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
5. Suthanthiran M. Transmembrane signalling via the T cell antigen receptor heterodimer and the CD2 antigen: a synergistic pathway for activation of T cells. Transplantation 1989; 47: 348.
6. Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987; 326: 400.
7. Kato K, Koyanagi M, Okada H, et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med 1992; 176: 1241.
8. Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151: 7249.
9. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031.
10. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
11. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607.
12. Freeman GJ, Borriello F, Hodes RJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice [see comments]. Science 1993; 262: 907.
13. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see comments]. Science 1993; 262: 909.
14. Wu Y, Guo Y, Liu Y. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J Exp Med 1993; 178: 1789.
15. Cerdan C, Martin Y, Courcoul M, et al. Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28: demonstration of combined transcriptional and post-transcriptional regulation. J Immunol 1992; 149: 2255.
16. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med 1994; 179: 299.
17. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721.
18. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 1992; 175: 353.
19. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
20. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
21. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg [see comments]. Science 1992; 257: 789.
22. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
23. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178: 1753.
24. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation 1992; 54: 286.
25. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082.
26. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701.
27. Altevogt P, Kohl U, Von HP, Lang E, Schirrmacher V. Antibody 12-15 cross-reacts with mouse Fc gamma receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein. Eur J Immunol 1989; 19: 341.
28. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374.
29. Furth ME, Davis LJ, Fleurdelys B, Scolnick EM. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol 1982; 43: 294.
30. Ruff MR, Gifford GE. Rabbit tumor necrosis factor: mechanism of action. Infect Immun 1981; 31: 380.
31. Fulmer R, Cramer AT, Liebelt RA, Liebelt AG. Transplantation of cardiac tissue into mouse ear. Am J Anat 1963; 113: 273.
32. Judd KP, Trentin JJ. Cardiac transplantation in mice. I. Factors influencing the take and survival of heterotopic grafts. 1971; 11: 298.
33. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993; 55: 901.
34. Finberg R, Burakoff SJ, Benacerraf B, Greene MI. The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. II. Evidence for antigen-specific suppressor T cells. J Immunol 1979; 123: 1210.
35. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 1983; 131: 2178.
36. Ledbetter JA, Herzenberg LA. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 1979; 47: 63.
37. Guy R, Foo PM, Sharrow SO, Hodes RJ. Subpopulations of fetal thymocytes defined by expression of T cell receptor/CD3 and IL-2 receptor: CD3 and IL-2 receptor alpha-chain are expressed on reciprocal cell populations. J Immunol 1991; 146: 418.
38. Ortega G, Robb RJ, Shevach EM, Malek TR. The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J Immunol 1984; 133: 1970.
39. Chavin KD, Qin L, Lin J, Woodward JE, Baliga P, Bromberg JS. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. Ann Surg 1993; 218: 492.
40. Bromberg JS, Chavin KD, Altevogt P, et al. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo. Transplantation 1991; 51: 219.
41. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993; 259: 974.
42. Maki T, Gottschalk R, Wood ML, Monaco AP. Specific unresponsiveness to skin allografts in anti-lymphocyte serum-treated, marrow-injected mice: participation of donor marrow-derived suppressor T cells. J Immunol 1981; 127: 1433.
43. Peterson JD, Karpus WJ, Clatch RJ, Miller SD. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol 1993; 23: 46.
44. Sheng TX, Miller RG. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation. J Exp Med 1992; 176: 407.
45. Yagita H, Okumura K, Nakauchi H. Molecular cloning of the murine homologue of CD2: homology of the molecule to its human counterpart T11. J Immunol 1988; 140: 1321.
46. Lorre K, Van DJ, Ceuppens JL. A bidirectional regulatory network involving IL 2 and IL 4 in the alternative CD2 pathway of T cell activation. Eur J Immunol 1990; 20: 1569.
47. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.